Literature DB >> 7889297

Regional effects of amphetamine, cocaine, nomifensine and GBR 12909 on the dynamics of dopamine release and metabolism in the rat brain.

F Karoum1, S J Chrapusta, R Brinjak, A Hitri, R J Wyatt.   

Abstract

1. The effects of single-dose regimens of amphetamine, cocaine, nomifensine and GBR 12909 on the dynamics of dopamine (DA) release and metabolism were evaluated in the frontal cortex, hypothalamus, nucleus accumbens and striatum. The regimens selected are known to produce substantial behavioural effects. 2. 3-Methoxytyramine (3MT) and 3,4-dihydroxyphenylacetic acid (DOPAC) rates of formation were used to assess DA metabolism by catechol-O-methyltransferase and monoamine oxidase respectively. The rate of formation of 3MT was used as an index of synaptic DA. The ratio and sum, respectively, of 3MT and DOPAC rates of formation were used to assess DA reuptake inhibition and turnover. 3. The effects of amphetamine on 3MT production and DOPAC steady-state levels were similar in all regions, suggesting similar pharmacodynamic actions. Amphetamine increased 3MT formation and steady-state levels, and reduced DOPAC steady-state levels. DOPAC formation was significantly reduced only in the nucleus accumbens and striatum. Total DA turnover remained unchanged except in the nucleus accumbens. Apparently, the amphetamine-induced increase in DA release occurred at the expense of intraneuronal DA metabolism and did not require stimulation of synthesis. 4. Nomifensine elevated 3MT formation in all regions. A similar effect was produced by cocaine except in the nucleus accumbens. GBR 12909 elevated 3MT production only in the hypothalamus, the striatum and the nucleus accumbens. 5. Cocaine selectively reduced DOPAC formation in the frontal cortex. Nomifensine increased and reduced, respectively, DOPAC formation in striatum and hypothalamus. GBR 12909 elevated DOPAC formation in all regions except the cortex, where pargyline did not reduce DOPAC levels in GBR 12909-treated rats. 6. Ratios and sum of 3MT and DOPAC rates of formation also exhibited wide regional variations for each drug. In contrast to the other drugs, the ratio was not increased after GBR 12909. Apparently, the DA uptake properties of this drug are poorly related to its in vivo effects on the ratio of 3MTproduction to that of DOPAC, which should increase when DA reuptake is inhibited.7. Total DA turnover was increased by GBR 12909 in the hypothalamus, nucleus accumbens and striatum, while cocaine and nomifensine increased it only in the nucleus accumbens and striatum respectively.8. It is concluded that:(a) 3MT and DOPAC rates of formation provide better indices of DA release and metabolism than do their steady-state concentrations.(b) Some effects of DA uptake blockers on DA transmission, especially those of nomifensine and cocaine, may be attributed to increased DA release.(c) Patterns of regional effects of psychostimulants on the dynamics of DA release and metabolism may be better biochemical correlates of stimulant-induced behaviours than would changes in any single region.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7889297      PMCID: PMC1510507          DOI: 10.1111/j.1476-5381.1994.tb17152.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  77 in total

1.  Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals.

Authors:  E Carboni; G L Tanda; R Frau; G Di Chiara
Journal:  J Neurochem       Date:  1990-09       Impact factor: 5.372

2.  Long-term administration of d-amphetamine: progressive augmentation of motor activity and stereotypy.

Authors:  D S Segal; A J Mandell
Journal:  Pharmacol Biochem Behav       Date:  1974 Mar-Apr       Impact factor: 3.533

Review 3.  Recent investigations on the mechanism of action of nomifensine.

Authors:  U Schacht; M Leven; H J Gerhards; P Hunt; J P Raynaud
Journal:  Int Pharmacopsychiatry       Date:  1982

4.  Nomifensine: a new potent inhibitor of dopamine uptake into synaptosomes from rat brain corpus striatum.

Authors:  P Hunt; M Kannengiesser; J Raynaud
Journal:  J Pharm Pharmacol       Date:  1974-05       Impact factor: 3.765

5.  Biochemical differentiation of amphetamine vs methylphenidate and nomifensine in rats.

Authors:  C Braestrup
Journal:  J Pharm Pharmacol       Date:  1977-08       Impact factor: 3.765

6.  Intracerebral dialysis: direct evidence for the utility of 3-MT measurements as an index of dopamine release.

Authors:  P L Wood; H S Kim; M R Marien
Journal:  Life Sci       Date:  1987-07-06       Impact factor: 5.037

7.  Heterogeneous binding of sigma radioligands in the rat brain and liver: possible relationship to subforms of cytochrome P-450.

Authors:  S B Ross
Journal:  Pharmacol Toxicol       Date:  1991-04

8.  On the significance of endogenous 3-methoxytyramine for the effects of centrally acting drugs on dopamine release in the rat brain.

Authors:  B H Westerink; S J Spaan
Journal:  J Neurochem       Date:  1982-03       Impact factor: 5.372

9.  Differential effects of certain dopaminergic drugs on the striatal concentration of dopamine metabolites, with special reference to 3-methoxytramine.

Authors:  F Ponzio; G Achilli; C Perego; S Algeri
Journal:  Neurosci Lett       Date:  1981-11-18       Impact factor: 3.046

10.  Effect of various centrally acting drugs on the efflux of dopamine metabolites from the rat brain.

Authors:  B H Westerink; R J Kikkert
Journal:  J Neurochem       Date:  1986-04       Impact factor: 5.372

View more
  9 in total

Review 1.  Effects of chronic neuroleptic treatment on dopamine release: insights from studies using 3-methoxytyramine.

Authors:  M F Egan; S Chrapusta; F Karoum; B K Lipska; R J Wyatt
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

Review 2.  Dopaminergic impact of cART and anti-depressants on HIV neuropathogenesis in older adults.

Authors:  Stephanie M Matt; Peter J Gaskill
Journal:  Brain Res       Date:  2019-08-21       Impact factor: 3.252

3.  Activation of glycogen synthase kinase-3 beta is required for hyperdopamine and D2 receptor-mediated inhibition of synaptic NMDA receptor function in the rat prefrontal cortex.

Authors:  Yan-Chun Li; Dong Xi; Joy Roman; Yue-Qiao Huang; Wen-Jun Gao
Journal:  J Neurosci       Date:  2009-12-09       Impact factor: 6.167

4.  Pharmacoterrorism: the potential role of psychoactive drugs in the Paris and Tunisian attacks.

Authors:  Guillaume Fond; Oliver Howes
Journal:  Psychopharmacology (Berl)       Date:  2016-01-11       Impact factor: 4.530

5.  Poor evidence for depolarization block but uncoupling of nigral from striatal dopamine metabolism after chronic haloperidol treatment in the rat.

Authors:  S J Chrapusta; M F Egan
Journal:  J Neural Transm (Vienna)       Date:  2005-08-05       Impact factor: 3.850

6.  Dopamine inactivation efficacy related to functional DAT1 and COMT variants influences motor response evaluation.

Authors:  Stephan Bender; Thomas Rellum; Christine Freitag; Franz Resch; Marcella Rietschel; Jens Treutlein; Christine Jennen-Steinmetz; Daniel Brandeis; Tobias Banaschewski; Manfred Laucht
Journal:  PLoS One       Date:  2012-05-23       Impact factor: 3.240

Review 7.  Gene-sex interactions in schizophrenia: focus on dopamine neurotransmission.

Authors:  Sean C Godar; Marco Bortolato
Journal:  Front Behav Neurosci       Date:  2014-03-06       Impact factor: 3.558

8.  Chronic cocaine induces HIF-VEGF pathway activation along with angiogenesis in the brain.

Authors:  Wei Yin; Kevin Clare; Qiujia Zhang; Nora D Volkow; Congwu Du
Journal:  PLoS One       Date:  2017-04-27       Impact factor: 3.240

9.  Comparative Neuropharmacology and Pharmacokinetics of Methamphetamine and Its Thiophene Analog Methiopropamine in Rodents.

Authors:  Silja Skogstad Tuv; Marianne Skov-Skov Bergh; Jannike Mørch Andersen; Synne Steinsland; Vigdis Vindenes; Michael H Baumann; Marilyn A Huestis; Inger Lise Bogen
Journal:  Int J Mol Sci       Date:  2021-11-05       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.